CheckMate 577 Update: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemotherapy

June 4-8, 2021; Online at https://conferences.asco.org/am
Compared with placebo, adjuvant nivolumab significantly prolonged disease-free survival in patients with resected EC/GEJC who had received neoadjuvant chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 392 KB
Released: June 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Phase II trial evaluating pemigatinib for previously treated mCRC with FGF/FGFR alterations, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

Updated data from the CheckMate 649 study of nivolumab + chemotherapy for advanced gastric/GEJ cancer and esophageal adenocarcinoma, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

MOUNTAINEER concordance analysis between breast and gastric algorithms for HER2 testing in mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

SUNLIGHT trial of the addition of bevacizumab to third-line TAS-102 in refractory mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings